FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
March 08, 2024 07:55 ET
|
UsAgainstAlzheimer's
WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the...
Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023
March 06, 2024 04:00 ET
|
Rentschler Biopharma SE
Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
February 29, 2024 17:51 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
February 28, 2024 09:15 ET
|
Virios Therapeutics
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
February 28, 2024 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
February 27, 2024 08:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
February 22, 2024 07:53 ET
|
SeaStar Medical Holding Corporation
SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
February 19, 2024 14:14 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of...
Alarming Study Reveals Safety Limits are Exceeded for Mercury Exposure from Dental Amalgams in Pregnant Women in the U.S.
February 14, 2024 11:00 ET
|
International Academy of Oral Medicine & Toxicology
A New Study Reveals that Mercury Exposure from Dental Amalgam Fillings in Pregnant Women Exceed Safety Limits
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
February 12, 2024 07:00 ET
|
Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video